FDA Peptide Compounding Status Update - May 2026 Audit
James MitchellMSc Biochemistry Current FDA Position
FDA’s current Category 2 explanation says these are nominated bulk drug substances that may be eligible for evaluation, but FDA has identified significant safety risks and does not intend to apply the more permissive Category 1 interim enforcement policy to them. FDA also says it may consider action under its general enforcement policies.
The practical takeaway: Category 2 is not a clearance signal. It is a risk and enforcement signal that requires substance-by-substance review.
Current High-Signal FDA Peptide Items
Category 2 and Safety-Risk Signals
FDA’s safety-risk page lists BPC-157 in 503A Category 2 and describes concerns including immunogenicity risk for certain routes, peptide-related impurity and API-characterization complexity, and limited safety information for proposed routes of administration.
The same FDA page also includes other peptide or peptide-adjacent substances that should be treated as higher-risk coverage topics, including cathelicidin LL-37, dihexa acetate, GHRP-2, GHRP-6, ibutamoren mesylate, ipamorelin acetate, kisspeptin-10, melanotan II, PEG-MGF, and others.
503A Bulk-Substance Status Is Separate
FDA’s 503A bulk-substance materials distinguish Category 1, Category 2, and Category 3 under the interim policy. Those categories are not a simple “legal / illegal” menu and should not be presented as approval status.
For example, a substance in Category 1 may be within the scope of FDA’s interim enforcement policy if conditions are met, while Category 2 is specifically flagged because FDA identified significant safety risks pending further evaluation.
July 2026 PCAC Review
FDA’s July 23-24, 2026 Pharmacy Compounding Advisory Committee notice includes several peptide-related bulk drug substance groups, including BPC-157, KPV, TB-500, MOTs-C, DSIP, Semax, and Epitalon-related substances.
That means some important peptide rows are unresolved rather than settled. PeptideUnicorn now tracks those as PCAC-review signals in the Regulatory Tracker.
What This Means for Readers
- Do not treat Category 2 as a green light for compounding.
- Do not assume 503A and 503B pathways are interchangeable.
- Do not assume a research-channel product has the same oversight as a prescribed or compounded medicine.
- For clinical decisions, use licensed clinicians and pharmacies and verify the applicable state and federal rules.
PeptideUnicorn does not prescribe, dispense, route care, or recommend research peptides for personal use.
Sources
- FDA: Bulk drug substances used in compounding under section 503A
- FDA: Certain bulk drug substances for compounding that may present significant safety risks
- FDA: 503A bulk drug substances update PDF
- FDA: July 23-24, 2026 PCAC meeting notice